Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit

Primary or acquired resistant mechanisms prevent the employment of individualized therapy with target drugs like the mTOR inhibitor everolimus (EVE) in hepatocellular carcinoma (HCC). The current study evaluated the effect of 1,25(OH)(2)Vitamin D (VitD) treatment on EVE sensitivity in established mo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Provvisiero, Donatella Paola, Negri, Mariarosaria, de Angelis, Cristina, Di Gennaro, Gilda, Patalano, Roberta, Simeoli, Chiara, Papa, Fortuna, Ferrigno, Rosario, Auriemma, Renata Simona, De Martino, Maria Cristina, Colao, Annamaria, Pivonello, Rosario, Pivonello, Claudia
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6690984/
https://ncbi.nlm.nih.gov/pubmed/31406139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-48081-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars